BPA Biosante Pharmaceuticals

BioSante Pharmaceuticals (AMEX: BPA) today announced that Stephen M. Simes, president and chief executive officer, will present a corporate overview at two upcoming conferences. The conferences are: The CIBC World Markets Israeli Conference on May 20, 2007 at 3:55 p.m. local time at the David Intercontinental, Tel Aviv. The RedChip Small-Cap Investor Conference on May 30, 2007 at 10:30 p.m. local time at the Ritz Carlton in San Francisco. A live audio webcast of BioSante�s presentation at the RedChip conference can be accessed on the internet by visiting www.biosantepharma.com. An archive of this presentation will be available at the same address. The CIBC World Markets Israeli Conference will have over 45 presentations by worldwide technology leaders. The RedChip Small-Cap Investor Conference will feature CEOs from fifty companies. About BioSante Pharmaceuticals, Inc. BioSante is developing a pipeline of hormone therapy products to treat both men and women. These hormone therapy products are gel formulations for transdermal administration that deliver bio-identical estradiol and testosterone. BioSante's lead products include Elestrin� (estradiol gel), developed through U.S. Food and Drug Administration (FDA) approval by BioSante, indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and LibiGel� (transdermal testosterone gel) in Phase III development for the treatment of female sexual dysfunction (FSD). The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion. The company also is developing its calcium phosphate nanotechnology (CaP) for novel vaccines, including hepatitis B, avian flu and biodefense vaccines for toxins such as anthrax, as well as a system for delivering drugs via alternative routes of administration. Additional information is available online at: www.biosantepharma.com.